Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Fleur Hiege Center for Skin Cancer Research, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Clin Exp Metastasis. 2024 Aug;41(4):403-411. doi: 10.1007/s10585-024-10267-5. Epub 2024 Jan 28.
The concept of liquid biopsy analysis has been established more than a decade ago. Since the establishment of the term, tremendous advances have been achieved and plenty of methods as well as analytes have been investigated in basic research as well in clinical trials. Liquid biopsy refers to a body fluid-based biopsy that is minimal-invasive, and most importantly, allows dense monitoring of tumor responses by sequential blood sampling. Blood is the most important analyte for liquid biopsy analyses, providing an easily accessible source for a plethora of cells, cell-derived products, free nucleic acids, proteins as well as vesicles. More than 12,000 publications are listed in PubMed as of today including the term liquid biopsy. In this manuscript, we critically review the current implications of liquid biopsy, with special focus on circulating tumor cells, and describe the hurdles that need to be addressed before liquid biopsy can be implemented in clinical standard of care guidelines.
液体活检分析的概念早在十多年前就已经确立。自该术语建立以来，已经取得了巨大的进展，并且在基础研究和临床试验中已经研究了大量的方法和分析物。液体活检是指基于体液的活检，具有微创性，最重要的是允许通过连续采血来密集监测肿瘤反应。血液是液体活检分析最重要的分析物，为大量细胞、细胞衍生产物、游离核酸、蛋白质和囊泡提供了一个易于获取的来源。截至今天，PubMed 中列出了超过 12000 篇包含液体活检术语的出版物。在本文中，我们批判性地回顾了液体活检的当前意义，特别关注循环肿瘤细胞，并描述了在液体活检能够纳入临床标准护理指南之前需要解决的障碍。
